Royalty Report: Drugs, Biotechnology, Diagnostic – Collection: 29280


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29280

License Grant
The Company entered into a License Agreement granting a three year exclusive world-wide license to manufacture and market DNA molecules, encoding one or more universal Epitopes, antibodies to the universal epitopes, any kits containing the referenced antibodies or DNA molecules, and any custom epitope-tagging services employing the referenced antibodies or DNA molecules.
Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 28035

License Grant
The University or Licensor granted rights to certain patents and technology to the Ireland-based Licensee. The agreement is a royalty-bearing, non-exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, distribute, Sell, offer to Sell, import, lease, loan or otherwise Commercialize Licensed Products in Licensee's ordinary course of business, within the Licensed Territory (worldwide) for use within Licensed Field. This Patent agreement is subsequent to a research agreement from which the relevant technology emerged.
License Property
The Licensed Subject Matter means protein and antibody based inventions. Patent Rights means the University's rights in information or discoveries covered by the University’s patent(s) or patent applications in the Licensed Territory for the following a.“VMP-Like Sequences of Pathogenic Borrelia”; and b.“VMP-Like Sequences of Pathogenic Borrelia Species and Strains”; and c.any patent(s) issuing from the foregoing applications; and d.any reissue, extension, revival or reexamination of the foregoing patent(s).
Field of Use
The Licensed Field means the use of Licensed Subject Matter to make, have made, use and Sell a protein or antibody-based human diagnostic test for Lyme disease.

IPSCIO Record ID: 860

License Grant
The Licensor grants the Licensee an exclusive, worldwide royalty-bearing license under the Intellectual Property to manufacture, have manufactured, market, package, warehouse, use ,sell, offer to sell, have sold, distribute, import into the Territory, export and otherwise dispose of Products in the Field of the treatment and prevention of viral infectious diseases in humans.
License Property
The Patent Rights arise from the following

U.S. Patent No. 5,658,762, entitled “DNA molecules, expression vectors, and host cells expressing antigenized antibodies” issued April 19, 1997.

U.S. Patent Application No. 09/300,959, entitled “STI and related methods” pending.

Field of Use
The Field is the treatment and prevention of viral infectious diseases in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.